<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit
         Document created using EDGARfilings PROfile 6.5.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; font-weight: bold;">As filed with the Securities and Exchange Commission on November 25, 2019</div>
    <div style="text-align: right; font-weight: bold;">No. 333-<a name="Text1"></a>______</div>
    <div style="text-align: center; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;">
      <div style="font-size: 14pt;">UNITED STATES</div>
    </div>
    <div style="text-align: center; font-weight: bold;"><font style="font-size: 14pt;">SECURITIES AND EXCHANGE COMMIS</font><font style="font-size: 14pt;">SION</font></div>
    <div style="text-align: center; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 14%; color: #000000;"></div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM S-8</div>
    <div style="text-align: center; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">UNDER</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div style="text-align: center; font-style: italic; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-style: italic; font-weight: bold;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 14%; color: #000000;"></div>
    <div style="text-align: center; font-style: italic; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-size: 24pt; font-weight: bold;">Bristol-Myers Squibb Company</div>
    <div style="text-align: center;">(Exact name of registrant as specified in its charter)</div>
    <div>&#160;
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="zc48e599d22004e04a135cd79ae139188">

          <tr>
            <td style="width: 49%;">
              <div style="text-align: center; font-weight: bold;">Delaware</div>
            </td>
            <td style="width: 2%;">
              <div>&#160;</div>
            </td>
            <td style="width: 49%;">
              <div>
                <div style="text-align: center; font-weight: bold;">22-0790350</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 49%;" rowspan="1">
              <div style="text-align: center;">(State or other Jurisdiction of Incorporation or Organization)</div>
            </td>
            <td style="width: 2%;" rowspan="1">&#160;</td>
            <td style="width: 49%;" rowspan="1">
              <div style="text-align: center;">(I.R.S. Employer Identification No.)</div>
            </td>
          </tr>

      </table>
    </div>
    <div> <br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">430 East 29th Street, 14th Floor, New York, New York 10016</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(212) 546-4000</div>
    <div style="text-align: center;">(Address including Zip Code of Principal Executive Offices)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Bristol-Myers Squibb Company 2017 Stock Incentive Plan</div>
    <div style="text-align: center; font-weight: bold;">Bristol-Myers Squibb Company 2014 Equity Incentive Plan</div>
    <div><br>
    </div>
    <div style="text-align: center;">(Full title of the plan)</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Sandra Leung, Esq.</div>
    <div style="text-align: center; font-weight: bold;">Bristol-Myers Squibb Company</div>
    <div style="text-align: center; font-weight: bold;">430 East 29th Street, 14th Floor</div>
    <div style="text-align: center; font-weight: bold;">New York, New York 10016</div>
    <div style="text-align: center; font-weight: bold;">(212) 546-3309</div>
    <div style="text-align: center;">(Name, address and telephone number, including area code, of agent for service)</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;">With a copy to:</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">Sophia Hudson, P.C.</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Kirkland &amp; Ellis LLP</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">601 Lexington Avenue</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">New York, New York 10022</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(212) 446-4800</div>
    <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; color: #000000; font-weight: bold;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 14%; color: #000000;"></div>
    <br>
    <div>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated
      filer,&#8221; &#8220;small reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z2dbe188afbaf4482bb9ab3af6db60b51" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 24.99%; vertical-align: top;">
            <div>Large accelerated filer</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>&#9746;</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div>Accelerated filer</div>
          </td>
          <td style="width: 10%; vertical-align: top;">
            <div>&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 24.99%; vertical-align: top;">
            <div>Non-accelerated filer</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>&#9744;</div>
          </td>
          <td style="width: 20%; vertical-align: top;">
            <div>Smaller reporting company</div>
          </td>
          <td style="width: 10%; vertical-align: top;">
            <div>&#9744;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 24.99%; vertical-align: top;">&#160;</td>
          <td style="width: 45%; vertical-align: top;">&#160;</td>
          <td style="width: 20%; vertical-align: top;">
            <div>Emerging growth company</div>
          </td>
          <td style="width: 10%; vertical-align: top;">
            <div>&#9744;</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act.&#160; &#160;&#160; &#9744;</div>
    <div style="text-align: center; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; font-weight: bold;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 14%; color: #000000;"></div>
    <div style="text-align: center; font-weight: bold;"><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" id="z040284429a754e6ab8a231d92d991355">

        <tr>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: top; border-bottom: 4px double rgb(0, 0, 0);" colspan="16">
            <div style="text-align: center; font-weight: bold;">CALCULATION OF REGISTRATION FEE</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 40%; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; font-weight: bold;">Title of securities to be registered</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; font-weight: bold;">Amount to be</div>
            <div style="text-align: center; font-weight: bold;">registered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;"> (1)</sup></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; font-weight: bold;">Proposed maximum</div>
            <div style="text-align: center; font-weight: bold;">offering price per unit</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; font-weight: bold;">Proposed maximum</div>
            <div style="text-align: center; font-weight: bold;">aggregate offering price</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; font-weight: bold;">Amount of</div>
            <div style="text-align: center; font-weight: bold;">registration fee<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 40%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div>Common Stock, par value $0.10 per share</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 13%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>
              <div>149,588,013</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 13%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>55.90</div>
          </td>
          <td style="background-color: #CCEEFF; border-bottom: 4px double #000000; border-right: 2px solid #000000; vertical-align: top; white-space: nowrap; width: 1%;" colspan="1"> <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup><br>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 13%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>
              <div>8,361,969,926.70</div>
            </div>
          </td>
          <td style="background-color: #CCEEFF; border-bottom: 4px double #000000; border-right: 2px solid #000000; vertical-align: top; white-space: nowrap; width: 1%;" colspan="1">
            <div> <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>
              <div>1,085,383.70</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 40%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);">
            <div>Bristol-Myers Squibb Contingent Value Rights (CVRs)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 13%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>14,215,025</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 13%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>2.34</div>
          </td>
          <td style="background-color: #FFFFFF; border-bottom: 4px double #000000; border-right: 2px solid #000000; vertical-align: top; white-space: nowrap; width: 1%;" colspan="1">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 13%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>33,263,158.50</div>
          </td>
          <td style="background-color: #FFFFFF; border-bottom: 4px double #000000; border-right: 2px solid #000000; vertical-align: top; white-space: nowrap; width: 1%;" colspan="1">
            <div><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup><br>
            </div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>$</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">
            <div>4,317.56</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z7714a901e1824c0985afcde40ecd6950" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top;">(1)</td>
              <td style="width: auto; vertical-align: top;">
                <div>This Registration Statement on Form S-8 (&#8220;<font style="font-weight: bold;">Registration Statement</font>&#8221;) registers offers and sales of 120,107,152 shares of common stock, par value $0.10 per share (&#8220;<font style="font-weight: bold;">Common













                    Stock</font>&#8221;), of Bristol-Myers Squibb Company (the &#8220;<font style="font-weight: bold;">Company</font>&#8221; or the &#8220;<font style="font-weight: bold;">Registrant</font>&#8221;) and 14,215,025 contingent value rights (&#8220;<font style="font-weight: bold;">CVRs</font>&#8221;) issuable to holders (other than former employees of Celgene Corporation at the effective time of the Merger) of certain stock options, restricted stock units, performance stock units and restricted stock awards of
                  Celgene Corporation (&#8220;<font style="font-weight: bold;">Celgene</font>&#8221;), in connection with the merger (&#8220;<font style="font-weight: bold;">Merger</font>&#8221;) of Burgundy Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;<font style="font-weight: bold;">Merger Sub</font>&#8221;), with and into Celgene, pursuant to the Agreement and Plan of Merger, dated as of January 2, 2019 (&#8220;<font style="font-weight: bold;">Merger Agreement</font>&#8221;), among the Company, Merger Sub
                  and Celgene. In addition, this Registration Statement registers 29,480,861 shares of Common Stock issuable to current employees of Celgene and future employees of the Company under the BMS Stock Plans (as defined below).&#160; Pursuant to Rule
                  416(A), the number of shares and CVRs being registered shall be adjusted to include any additional shares and CVRs which may become issuable as a result of stock splits, stock dividends or similar transactions in accordance with the
                  anti-dilution provisions of the BMS Stock Plans and agreements evidencing outstanding awards thereunder.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="zfcfbb8b93f5e499dacc530061ba2b0c5" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top;">(2)</td>
              <td style="width: auto; vertical-align: top;">
                <div>Estimated solely for the purpose of computing the registration fee pursuant to Rule 457(h) and Rule 457(c) under the Securities Act of 1933 (&#8220;<font style="font-weight: bold;">Securities Act</font>&#8221;), as amended. The price per share of
                  Common Stock is based on the average of the high and low prices reported for a share of Common Stock on the New York Stock Exchange on November 20, 2019.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z38b3052e30d64a668eddfddb55c791c1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top;">(3)</td>
              <td style="width: auto; vertical-align: top;">
                <div>Estimated solely for the purpose of computing the registration fee pursuant to Rule 457(h) and Rule 457(c) under the Securities Act. The price per CVR is based on the average of the high and low prices reported for a CVR on the New
                  York Stock Exchange on November 21, 2019.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z9d8b87da818445daae1e47dd32e08290" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt; vertical-align: top;">(4)</td>
              <td style="width: auto; vertical-align: top;">
                <div>Determined in accordance with Section 6(b) of the Securities Act at a rate equal to $129.80 per $1,000,000 of the proposed maximum aggregate offering price.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: center; font-weight: bold;">EXPLANATORY NOTE</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">On November 20, 2019, upon the effectiveness of the Merger (the &#8220;<font style="font-weight: bold;">Effective Time</font>&#8221;), Celgene became a wholly-owned subsidiary of the Company. Pursuant to the Merger Agreement, at the
      Effective Time:</div>
    <div>&#160;</div>
    <div style="text-align: justify;">
      <div>
        <table cellspacing="0" cellpadding="0" id="z906f138c62514ebf800511efd979b41e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Each Celgene In-the-Money Option (as defined herein) was assumed by the Company and converted into (i) an option (an &#8220;<font style="font-weight: bold;">Assumed In-the-Money Option</font>&#8221;) to purchase, on the same terms and conditions
                  as applied to each such Celgene In-the-Money Option immediately prior to the Effective Time, shares of Common Stock, except that (A) the number of shares of Common Stock subject to such Assumed In-the-Money Option is equal to the product
                  of (x) the number of shares of Celgene common stock that were subject to such Celgene In-the-Money Option immediately prior to the Effective Time, multiplied by (y) the Equity Award Exchange Ratio (as defined herein) (rounded down to the
                  nearest whole number), and (B) the per-share exercise price is equal to the quotient of (x) the exercise price per share of Celgene common stock at which such Celgene In-the-Money Option was exercisable, divided by (y) the Equity Award
                  Exchange Ratio (rounded up to the nearest whole cent), and (ii) the right to receive (A) if such Celgene In-the-Money Option was vested prior to the Effective Time, one CVR for each share of Celgene common stock underlying such Celgene
                  In-the-Money Option immediately prior to the Effective Time or (B) if such Celgene In-the-Money Option was not vested immediately prior to the Effective Time, immediately upon, and subject to, the vesting of the Assumed In-the Money
                  Option, the Unvested Equity Award CVR Consideration (as defined herein). Each Assumed In-the-Money Option will continue to have the same terms and conditions as applied to the corresponding Celgene In-the-Money Option immediately prior to
                  the Effective Time.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">
      <div>
        <table cellspacing="0" cellpadding="0" id="z73394bea09a1456d86d8d0664c7718cc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><font style="color: #000000;">Each Celgene Out-of-the-Money Option </font>(as defined herein)<font style="color: rgb(0, 0, 0);"> was assumed by the Company and converted into an option (an &#8220;</font><font style="font-weight: bold; color: rgb(0, 0, 0);">Assumed Out-of-the-Money Stock Option</font><font style="color: rgb(0, 0, 0);">&#8221;) to purchase, on the same terms and conditions as applied to each such Celgene Out-of-the-Money Option immediately prior to the
                    Effective Time, shares of Common Stock, except that the number of shares of Common Stock subject to such Assumed Out-of-the-Money Stock Option is equal to the product of (i) the number of shares of Celgene common stock that were subject
                    to such Celgene Out-of-the-Money Option immediately prior to the Effective Time, multiplied by (ii) the Out-of-the-Money Option Exchange Ratio (as defined herein) (rounded down to the nearest whole number), and the per-share exercise
                    price is equal the quotient of (A) the exercise price per share of Celgene common stock at which such Celgene Out-of-the-Money Option was exercisable, divided by (B) the Out-of-the-Money Option Exchange Ratio (rounded up to the nearest
                    whole cent). Each Assumed Out-of-the-Money Stock Option will continue to have the same terms and conditions as applied to the corresponding Celgene Out-of-the-Money Option immediately prior to the Effective Time.</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">
      <div>
        <table cellspacing="0" cellpadding="0" id="zfa1cc44e6e1b47f6b3efe2472b3798bc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">3.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><font style="color: #000000;">Each restricted stock unit award with respect to shares of Celgene common stock outstanding under any Celgene Stock Plan (as defined herein) that vests solely based on the passage of time (&#8220;</font><font style="font-weight: bold; color: #000000;">Celgene RSU Award</font><font style="color: #000000;">&#8221;) was assumed by the Company and converted into (i) a restricted unit award (an &#8220;</font><font style="font-weight: bold; color: #000000;">Assumed













                    Restricted Unit Award</font><font style="color: #000000;">&#8221;) that settles in a number of shares of Common Stock equal to (A) the number of shares of Celgene common stock underlying the Celgene RSU Award immediately prior to the
                    Effective Time, multiplied by (B) the Equity Award Exchange Ratio (rounded up to the nearest whole number of shares) and (ii) the right to receive, subject to the vesting of the Assumed Restricted Unit Award, the Unvested Equity Award
                    CVR Consideration. Each Assumed Restricted Unit Award will continue to have the same terms and conditions as applied to the corresponding Celgene RSU Award immediately prior to the Effective Time.</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify;">
      <div>
        <table cellspacing="0" cellpadding="0" id="zb22b51338fde40179e404469dea0ee06" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">4.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><font style="color: #000000;">Each restricted stock unit award with respect to shares of Celgene common stock outstanding under any Celgene Stock Plan that vests based on the achievement of performance goals (&#8220;</font><font style="font-weight: bold; color: #000000;">Celgene PSU Award</font><font style="color: #000000;">&#8221;) was assumed by the Company and converted into (i) a restricted stock unit award (an &#8220;</font><font style="font-weight: bold; color: #000000;">Assumed Performance Unit Award</font><font style="color: #000000;">&#8221;) that settles in a number of shares of Common Stock equal to the product of (A) the number of shares of Celgene common stock underlying the Celgene PSU Award
                    immediately prior to the Effective Time (determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately
                    preceding the Effective Time) multiplied by (B) the Equity Award Exchange Ratio (rounded up to the nearest whole number of shares), and (ii) the right to receive, subject to the vesting of the Assumed Performance Unit Award, the
                    Unvested Equity Award CVR Consideration. Each Assumed Performance Unit Award will continue to have the same terms and conditions as applied to the corresponding Celgene PSU Award (other than performance-based vesting conditions)
                    immediately prior to the Effective Time.</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify;">
      <div>
        <table cellspacing="0" cellpadding="0" id="zf0dd0e98b3444a0f85dae091249806db" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; align: right;">5.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div><font style="color: #000000;">Each restricted stock award with respect to shares of Celgene common stock outstanding under any Celgene Stock Plan that vests based on the passage of time and/or the achievement of performance goals (&#8220;</font><font style="font-weight: bold; color: #000000;">Celgene RSA</font><font style="color: #000000;">&#8221;) was assumed by the Company and converted into (i) a restricted stock award (an &#8220;</font><font style="font-weight: bold; color: #000000;">Assumed













                    Restricted Stock Award</font><font style="color: #000000;">&#8221;) that settles in a number of shares of Common Stock equal to (A) the number of shares of Celgene common stock underlying the Celgene RSA immediately prior to the Effective
                    Time multiplied by (B) the Equity Award Exchange Ratio (rounded up to the nearest whole number of shares), and (ii) the right to receive, subject to the vesting of the Assumed Restricted Stock Award, the Unvested Equity Award CVR
                    Consideration. Each Assumed Restricted Stock Award will continue to have the same terms and conditions as applied to the corresponding Celgene RSA.</font></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div>&#160;</div>
    <div style="color: #000000;">For purposes of this Registration Statement:</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">&#8220;<font style="font-style: italic;">BMS Stock Plans</font>&#8221; means the Bristol-Myers Squibb Company 2017 Stock Incentive Plan (F/K/A Celgene Corporation 2017 Stock Incentive Plan) and the Bristol-Myers
      Squibb Company 2014 Equity Incentive Plan (F/K/A Celgene Corporation 2014 Equity Incentive Plan), each of which was formerly a Celgene equity incentive plan and was assumed by the Company in connection with the Merger.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">&#8220;<font style="font-style: italic;">Celgene In-the-Money Option</font>&#8221; means a compensatory option to purchase shares of Celgene common stock under any Celgene Stock Plan for which the per share
      exercise price as of immediately prior to the Effective Time is less than the Celgene Stock Price.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">&#160;&#8220;<font style="font-style: italic;">Celgene Stock Plans</font>&#8221; means the Celgene Corporation 2017 Stock Incentive Plan and the Celgene Corporation 2014 Equity Incentive Plan. In connection with the
      Merger, the Celgene Corporation 2017 Stock Incentive Plan was assumed, amended and renamed by the Company as the Bristol-Myers Squibb Company 2017 Stock Incentive Plan. The Celgene Corporation 2014 Equity Incentive Plan was assumed, amended and
      renamed by the Company as the Bristol-Myers Squibb Company 2014 Equity Incentive Plan.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">&#8220;<font style="font-style: italic;">Celgene Stock Price</font>&#8221; means $109.4009.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">&#8220;<font style="font-style: italic;">Celgene Out-of-the-Money Option</font>&#8221; means a compensatory option to purchase shares of Celgene common stock under any Celgene Stock Plan for which per share
      exercise price as of immediately prior to the Effective Time equals or exceeds the Celgene Stock Price.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">&#160;&#8220;<font style="font-style: italic;">CVR Agreement</font>&#8221; means the Contingent Value Rights Agreement, dated November 20, 2019 among the Company and Equiniti Trust Company, as trustee, in favor of each
      person who from time to time holds one or more CVRs.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">&#8220;<font style="font-style: italic;">Equity Award Exchange Ratio</font>&#8221; means 1.86.</div>
    <div>&#160;</div>
    <div style="color: #000000;">&#8220;<font style="font-style: italic;">Out-of-the-Money Option Exchange Ratio</font>&#8221; means 1.87.</div>
    <div>&#160;</div>
    <div style="text-align: justify; color: #000000;">&#8220;<font style="font-style: italic;">Unvested Equity Award CVR Consideration</font>&#8221; means, if the vesting date of the unvested Celgene In-the-Money Option, the Celgene RSU Award, the Celgene PSU Award or
      the Celgene RSA, as applicable, occurs (i) prior to the milestone payment record date and the termination date under the CVR Agreement, one CVR in respect of each share of Celgene common stock underlying such Celgene In-the-Money Option, Celgene RSU
      Award, Celgene PSU Award, or Celgene RSA, as applicable, immediately prior to the Effective Time, (ii) on or after the milestone payment record date under the CVR Agreement, a cash payment equal to the milestone payment under the CVR Agreement in
      respect of each share of Celgene common stock underlying such In-the-Money Option, Celgene RSU Award, Celgene PSU Award or Celgene RSA, as applicable, immediately prior to the Effective Time, or (iii) on or after the termination date under the CVR
      Agreement and the CVR milestone under the CVR Agreement was not achieved prior to such termination date, no additional consideration.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">PART I</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The information required by Item 1 and Item 2 of Part I of Form S-8 is omitted from this filing in accordance with Rule 428 under the Securities Act and the introductory note to Part I of Form S-8.
      The documents containing the information specified in Part I will be delivered to the participants in the plan covered by this Registration Statement as required by Rule 428(b)(1).</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">PART II</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z345299ca0c2e46db9a6fd1d27405650b" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left; font-weight: bold;">Item 3.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left; font-weight: bold;">Incorporation of Documents by Reference</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The following documents filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">Commission</font>&#8221;) by Company pursuant to the Securities Act and the Securities
      Exchange Act of 1934, as amended (the &#8220;<font style="font-weight: bold;">1934 Act</font>&#8221;) are incorporated herein by reference:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a) The Company&#8217;s Annual Report on Form 10-K for the fiscal year ended <a href="http://www.sec.gov/Archives/edgar/data/14272/000001427219000047/bmy-20181231x10xk.htm">December 31, 2018</a> (filed
      with the Commission on February 25, 2019).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b) The information specifically incorporated by reference into the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended <a href="http://www.sec.gov/Archives/edgar/data/14272/000001427219000047/bmy-20181231x10xk.htm">December 31, 2018</a> from the Company&#8217;s definitive proxy statement on Schedule 14A (filed with the Commission on <a href="http://www.sec.gov/Archives/edgar/data/14272/000104746919002763/a2238565zdef14a.htm">April 30, 2019</a>).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c) The Company&#8217;s Quarterly Reports on Form 10-Q for the quarter ended <a href="http://www.sec.gov/Archives/edgar/data/14272/000001427219000107/bmy-20190331x10q.htm">March 31, 2019</a> (filed with
      the Commission on April 25, 2019), for the quarter ended <a href="http://www.sec.gov/Archives/edgar/data/14272/000001427219000160/bmy-20190630x10q.htm">June 30, 2019</a> (filed with the Commission on July 25, 2019) and for the quarter ended <a href="http://www.sec.gov/Archives/edgar/data/14272/000001427219000194/bmy-20190930x10q.htm">September 30, 2019</a> (filed with the Commission on October 31, 2019).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(d) The Company&#8217;s Current Reports on Form 8-K filed with the Commission on <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119000175/form8k.htm">January 3, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119000360/s002621x1_8k.htm">January 4, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119001355/s002621x7_8k.htm">January 22, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119001955/s002621x12_8k.htm">January 30, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119004566/s002621x29_8k.htm">March 8, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119004564/s002621x24_8k.htm">March 8, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119005591/s002621x42_8k.htm">March 26, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119006510/s002621x44_8k.htm">April 4, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119007046/form8k.htm">April 12, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119007225/nc1000119x1_8k.htm">April 17, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119008191/nc10001539x1_8k.htm">May 1, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119008115/form8k.htm">May 1, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119008217/nc10001539x2_8k.htm">May 2, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119008676/nc10001539x3_8k.htm">May 8, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119009278/nc10001974x1_8k.htm">May 16, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119009779/nc10002137x1_8k.htm">May 24, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119010115/nc10002326x1_8k.htm">May 30, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119010432/nc10002432x1_8k.htm">June 5, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119011398/form8k.htm">June 24, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119011905/form8k.htm">June 28, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119012029/form8k.htm">July 1, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119015573/form8k.htm">August 26, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119016607/form8k.htm">September 12, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119017072/form8k.htm">September 23, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119018099/form8k.htm">October 8, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119018644/form8k.htm">October 18, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119019355/form8k.htm">October 30, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119019582/form8k.htm">November 1, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119019765/form8k.htm">November 5, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119019972/form8k.htm">November 7, 2019</a>,&#160; <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119020255/form8k.htm">November 12, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119020720/form8k.htm">November 15, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119020668/form8k.htm">November 15, 2019</a>, <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119021048/form8k.htm">November 20, 2019</a> and <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119021261/form8k.htm">November 22, 2019</a>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(e) The description of the Company&#8217;s capital stock and the CVRs, which is contained in the Company&#8217;s Registration Statement on <a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119002275/s002620x2_s4a.htm">Form S-4</a> (No. 333-229464) (filed with the Commission on February 1, 2019), including any amendments or supplements thereto.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(f) All future reports filed pursuant to Section 13(a) and 15(d) of the 1934 Act by the Company since the end of the fiscal year covered by the annual report referred to in (a) above; provided,
      however, that the foregoing shall not include the incorporation by reference of any information furnished pursuant to Items 2.02, 7.01 or 9.01 of Form 8-K.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">In addition, all documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this
      Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in the Registration Statement and to be a part hereof from the
      date of the filing of such documents (other than current reports furnished under Items 2.02, 7.01 or 9.01 of Form 8-K). Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
      or superseded for purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein) modifies or supersedes
      such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zef646dc55517449abb321502f417b337" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left; font-weight: bold;">Item 4.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left; font-weight: bold;">Description of Securities.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z274392ab703b479484b592284d65a13b" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left; font-weight: bold;">Item 5.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left; font-weight: bold;">Interests of Named Experts and Counsel.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">None.</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z95a272e4bd5b4d48ab962c30bf9a222a" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left; font-weight: bold;">Item 6.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left; font-weight: bold;">Indemnification of Directors and Officers.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Section 145 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;) provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses
      (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement in connection with specified actions, suits or proceedings, whether civil, criminal, administrative or investigative (other than an action by or in the right of the
      corporation&#8212;a &#8220;derivative action&#8221;), if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal actions or proceedings, had no reasonable
      cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection with the
      defense or settlement of such action, and the DGCL requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The DGCL provides that it is not exclusive of other
      indemnification that may be granted by a corporation&#8217;s by-laws, disinterested director vote, stockholder vote, agreement or otherwise.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Under the terms of our Bylaws and subject to the applicable provisions of Delaware law, we have agreed to indemnify each of our directors and officers and, subject to the discretion of the board of
      directors, any other person, against expenses incurred or paid in connection with any claim made against such director or officer or any actual or threatened action, suit or proceeding in which such director or officer may be involved by reason of
      being or having been a director or officer of us, or of serving or having served at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action taken
      or not taken by such director or officer in such capacity, and against the amount or amounts paid by such director or officer in settlement of any such claim, action, suit or proceeding or any judgment or order entered therein.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Section 102(b)(7) of the DGCL permits a provision in the certificate of incorporation of each corporation organized thereunder, such as the Company, eliminating or limiting, with certain exceptions,
      the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. The Company&#8217;s Amended and Restated Certificate of Incorporation eliminates the liability of directors <font style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);">for monetary damages for breach of fiduciary duty</font> to the extent permitted by the DGCL.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">The Company carries directors&#8217; and officers&#8217; liability insurance that covers certain liabilities and expenses of its directors and officers.</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z39899cdc963045239c7dbc4d10aec9d6" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left; font-weight: bold;">Item 7.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left; font-weight: bold;">Exemption from Registration Claimed.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">Not applicable.</div>
    <div style="text-indent: 36pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z447a357a29ec4682be50d847988c4a17" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left; font-weight: bold;">Item 8.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left; font-weight: bold;">Exhibits.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zcae7cca5001443b3b93feb4f9f07a625" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 12%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div>
              <div style="font-weight: bold; text-align: center;">Exhibit</div>
              <div style="font-weight: bold; text-align: center;">Number</div>
            </div>
          </td>
          <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">4.1</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Amended and Restated Certificate of Incorporation of Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit 3a to Bristol Myers-Squibb Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30,
              2005).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;">4.1A</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Certificate of Correction to the Amended and Restated Certificate of Incorporation, effective as of December 24, 2009 (incorporated herein by reference to Exhibit 3b to Bristol Myers-Squibb Company&#8217;s Annual Report on Form 10-K for the
              fiscal year ended December 31, 2010).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">4.1B</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective as of May 7, 2010 (incorporated herein by reference to Exhibit 3a to Bristol Myers-Squibb Company&#8217;s Current Report on Form 8-K filed on May 10,
              2010).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;">4.1C</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective as of May 7, 2010 (incorporated herein by reference to Exhibit 3b to Bristol Myers-Squibb Company&#8217;s Current Report on Form 8-K filed on May 10,
              2010).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">4.2</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Bylaws of Bristol-Myers Squibb Company, as amended as of November 2, 2016 (incorporated herein by reference to Exhibit 3.1 to Bristol Myers-Squibb Company&#8217;s Current Report on Form 8-K filed on November 4, 2016).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;">4.3</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Contingent Value Rights Agreement, between Bristol Myers Squibb Company and Equiniti Trust Company, dated November 20, 2019 (incorporated by reference to Exhibit 4.1 to Bristol Myers-Squibb Company&#8217;s Form 8-K dated November 20, 2019 and
              filed on November 20, 2019).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">5.1*</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Opinion of Kirkland &amp; Ellis LLP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;">23.1*</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Consent of Deloitte &amp; Touche LLP Independent Registered Public Accounting Firm of Bristol-Myers Squibb Company.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">23.2*</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Consent of KPMG LLP, independent registered public accounting firm of Celgene Corporation.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;">23.3*</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Consent of Kirkland &amp; Ellis LLP (included in Exhibit 5.1).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">24.1</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Powers of Attorney (included in the signature pages hereof).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;">99.1*</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(255, 255, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Bristol-Myers Squibb Company 2017 Stock Incentive Plan (F/K/A Celgene Corporation 2017 Stock Incentive Plan).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">99.2 *</div>
          </td>
          <td style="width: 2%; vertical-align: top; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>
          <td style="width: 86%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Bristol-Myers Squibb Company 2014 Equity Incentive Plan (F/K/A Celgene Corporation 2014 Equity Incentive Plan).</div>
          </td>
        </tr>

    </table>
    <div><font style="font-weight: bold;"> <br>
      </font></div>
    <div><font style="font-weight: bold;">*</font>Filed herewith</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zc66cc98aca1d4a59b0bb97c9f9dae01e" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: left; font-weight: bold;">Item 9.</div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: left; font-weight: bold;">Undertakings.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(a) The undersigned registrant hereby undertakes:</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;">(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;">(ii) To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which,
      individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
      securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (&#167;
      230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration
      statement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;">(iii) To include any material information with respect to the plans of distribution not previously disclosed in this registration statement or any material change to such
      information in this registration statement;</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 36pt;"><font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included
      in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are
      incorporated by reference in this registration statement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
      relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font> offering thereof.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section
      13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
      registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <font style="font-style: italic;">bona fide</font>
      offering thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant, pursuant to the foregoing
      provisions or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
      that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or
      proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a
      court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</div>
    <div style="text-align: justify; text-indent: 36pt;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
      and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on the 25th day of November, 2019.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z6b90f99d60394d18a5ff68247595956d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: justify; font-weight: bold;">BRISTOL-MYERS SQUIBB COMPANY</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify;">By:</div>
          </td>
          <td style="width: 47%; vertical-align: top; border-bottom: 2px solid black;">
            <div style="text-align: justify;">/s/ <font style="color: #000000;">Sandra Leung</font></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0);">Sandra Leung</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 3%; vertical-align: top;">&#160;</td>
          <td style="width: 47%; vertical-align: top;">
            <div style="text-align: justify; color: rgb(0, 0, 0); font-style: italic;">Executive Vice President and General Counsel</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="POWEROFATTORNEY"><!--Anchor--></a>POWER OF ATTORNEY</div>
    <div>&#160;</div>
    <div style="background-color: #FFFFFF;">
      <div style="text-align: justify; text-indent: 23.05pt; color: #000000;">Each person whose signature appears below constitutes and appoints Sandra Leung and Katherine R. Kelly as his or her true and lawful attorneys-in-fact and agents, with full power
        of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign the name of each of the undersigned in his or her capacity to any and all amendments (including any post-effective
        amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such said attorney-in-fact and agent full power and
        authority to do and perform each and every act and thing necessary or advisable to be done, as fully to all intents and purposes as the undersigned might or could do in person, and each of the undersigned hereby ratifies and confirms that the said
        attorney-in-fact or agent shall do or cause to be done by virtue hereof.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 23.05pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.</div>
      <div><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3ad68a8ed3e54de587d87d9d09a000f6">

            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-weight: bold;">
                  <div style="text-align: center;">Signature</div>
                </div>
              </td>
              <td style="width: 2%; vertical-align: bottom; font-weight: bold; text-align: center; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-weight: bold;">
                  <div style="text-align: center;">Title</div>
                </div>
              </td>
              <td style="width: 2%; vertical-align: bottom; font-weight: bold; text-align: center; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="font-weight: bold;">
                  <div style="text-align: center;">Date</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Giovanni Caforio</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Chief Executive Officer and Director</div>
                <div style="text-align: center; font-style: italic;">(Principal Executive Officer)</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Giovanni Caforio, M.D.</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ David V. Elkins</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Chief Financial Officer</div>
                <div style="text-align: center; font-style: italic;">(Principal Financial Officer)</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">David V. Elkins</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Karen M. Santiago</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Senior Vice President and Corporate Controller</div>
                <div style="text-align: center; font-style: italic;">(Principal Accounting Officer)</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Karen M. Santiago</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Vicki L. Sato</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Lead Independent Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Vicki L. Sato, Ph.D.</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Peter J. Arduini</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Peter J. Arduini</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Robert Bertolini</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Robert Bertolini</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Matthew W. Emmens</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Matthew W. Emmens</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Michael Grobstein</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Michael Grobstein</div>
              </td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>

        </table>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Alan J. Lacy</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Alan J. Lacy</div>
              </td>
              <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: middle;">&#160;</td>
              <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: middle;">&#160;</td>
              <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Dinesh C. Paliwal</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Dinesh C. Paliwal</div>
              </td>
              <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: middle;">&#160;</td>
              <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: middle;">&#160;</td>
              <td style="width: 2%; vertical-align: middle;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Theodore R. Samuels</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Theodore R. Samuels</div>
              </td>
              <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: top;">&#160;</td>
              <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Gerald L. Storch</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Gerald L. Storch</div>
              </td>
              <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: top;">&#160;</td>
              <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">/s/ Karen H. Vousden</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center; font-style: italic;">Director</div>
              </td>
              <td style="width: 2%; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom; padding-bottom: 2px;">
                <div style="text-align: center;">&#160;November 25, 2019</div>
              </td>
            </tr>
            <tr>
              <td style="width: 35%; vertical-align: top; border-top: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">Karen H. Vousden, Ph.D.</div>
              </td>
              <td style="width: 2%; vertical-align: top;" colspan="1">&#160;</td>
              <td style="width: 38%; vertical-align: bottom;">&#160;</td>
              <td style="width: 2%; vertical-align: bottom;" colspan="1">&#160;</td>
              <td style="width: 23%; vertical-align: bottom;">&#160;</td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
    </div>
    <div></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z755813ada5404c509900789ba7fab99e" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/14272/000119312505156446/dex3a.htm">4.1</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Amended and Restated Certificate of Incorporation of Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit 3a to Bristol Myers-Squibb Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30,
              2005).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/14272/000119312511040120/dex3b.htm">4.1A</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Certificate of Correction to the Amended and Restated Certificate of Incorporation, effective as of December 24, 2009 (incorporated herein by reference to Exhibit 3b to Bristol Myers-Squibb Company&#8217;s Annual Report on Form 10-K for the
              fiscal year ended December 31, 2010).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/14272/000119312510114770/dex3a.htm">4.1B</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective as of May 7, 2010 (incorporated herein by reference to Exhibit 3a to Bristol Myers-Squibb Company&#8217;s Current Report on Form 8-K filed on May 10,
              2010).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/14272/000119312510114770/dex3b.htm">4.1C</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective as of May 7, 2010 (incorporated herein by reference to Exhibit 3b to Bristol Myers-Squibb Company&#8217;s Current Report on Form 8-K filed on May 10,
              2010).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/14272/000156761916003171/s001466x1_ex3-1.htm">4.2</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Bylaws of Bristol-Myers Squibb Company, as amended as of November 2, 2016 (incorporated herein by reference to Exhibit 3.1 to Bristol Myers-Squibb Company&#8217;s Current Report on Form 8-K filed on November 4, 2016).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;"><a href="http://www.sec.gov/Archives/edgar/data/14272/000114036119021048/ex4_1.htm">4.3</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Contingent Value Rights Agreement, between Bristol Myers Squibb Company and Equiniti Trust Company, dated November 20, 2019 (incorporated by reference to Exhibit 4.1 to Bristol Myers-Squibb Company&#8217;s Form 8-K dated November 20, 2019 and
              filed on November 20, 2019).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="ex5_1.htm">5.1*</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Opinion of Kirkland &amp; Ellis LLP.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;"><a href="ex23_1.htm">23.1*</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Consent of Deloitte &amp; Touche LLP Independent Registered Public Accounting Firm of Bristol-Myers Squibb Company.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="ex23_2.htm">23.2*</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Consent of KPMG LLP, independent registered public accounting firm of Celgene Corporation.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;"><a href="ex5_1.htm">23.3*</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Consent of Kirkland &amp; Ellis LLP (included in Exhibit 5.1).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="#POWEROFATTORNEY">24.1</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Powers of Attorney (included in the signature pages hereof).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div style="text-align: center;"><a href="ex99_1.htm">99.1*</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(255, 255, 255);">
            <div>Bristol-Myers Squibb Company 2017 Stock Incentive Plan (F/K/A Celgene Corporation 2017 Stock Incentive Plan).</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.11%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;"><a href="ex99_2.htm">99.2*</a></div>
          </td>
          <td style="width: 88.89%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div>Bristol-Myers Squibb Company 2014 Equity Incentive Plan (F/K/A Celgene Corporation 2014 Equity Incentive).&#160; Plan).</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>*Filed herewith</div>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
[{"type": "S-8", "sequence": "1", "filename": "forms8.htm", "description": "S-8", "secsgml_size_bytes": 113186}]
{"company-data": {"conformed-name": "BRISTOL MYERS SQUIBB CO", "cik": "0000014272", "assigned-sic": "2834", "irs-number": "220790350", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-235254", "film-number": "191247033"}, "business-address": {"street1": "430 E. 29TH STREET", "street2": "14 FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10016", "phone": "2125464000"}, "mail-address": {"street1": "430 E. 29TH STREET", "street2": "14 FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10016"}, "former-company": {"former-conformed-name": "BRISTOL MYERS CO", "date-changed": "19891012"}}
As filed with the Securities and Exchange Commission on November 25, 2019
No. 333-
______
UNITED STATES
SECURITIES AND EXCHANGE COMMIS
SION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Bristol-Myers Squibb Company
(Exact name of registrant as specified in its charter)
Delaware
22-0790350
(State or other Jurisdiction of Incorporation or Organization)
(I.R.S. Employer Identification No.)
430 East 29th Street, 14th Floor, New York, New York 10016
(212) 546-4000
(Address including Zip Code of Principal Executive Offices)
Bristol-Myers Squibb Company 2017 Stock Incentive Plan
Bristol-Myers Squibb Company 2014 Equity Incentive Plan
(Full title of the plan)
Sandra Leung, Esq.
Bristol-Myers Squibb Company
430 East 29th Street, 14th Floor
New York, New York 10016
(212) 546-3309
(Name, address and telephone number, including area code, of agent for service)
With a copy to:
Sophia Hudson, P.C.
Kirkland & Ellis LLP
601 Lexington Avenue
New York, New York 10022
(212) 446-4800
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of "large accelerated filer," "accelerated
      filer," "small reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☒
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the
      Securities Act.     ☐
CALCULATION OF REGISTRATION FEE
Title of securities to be registered
Amount to be
registered
(1)
Proposed maximum
offering price per unit
Proposed maximum
aggregate offering price
Amount of
registration fee
(4)
Common Stock, par value $0.10 per share
149,588,013
$
55.90
(2)
$
8,361,969,926.70
(2)
$
1,085,383.70
Bristol-Myers Squibb Contingent Value Rights (CVRs)
14,215,025
$
2.34
(3)
$
33,263,158.50
(3)
$
4,317.56
(1)
This Registration Statement on Form S-8 ("
Registration Statement
") registers offers and sales of 120,107,152 shares of common stock, par value $0.10 per share ("
Common

                    Stock
"), of Bristol-Myers Squibb Company (the "
Company
" or the "
Registrant
") and 14,215,025 contingent value rights ("
CVRs
") issuable to holders (other than former employees of Celgene Corporation at the effective time of the Merger) of certain stock options, restricted stock units, performance stock units and restricted stock awards of
                  Celgene Corporation ("
Celgene
"), in connection with the merger ("
Merger
") of Burgundy Merger Sub, Inc., a wholly-owned subsidiary of the Company ("
Merger Sub
"), with and into Celgene, pursuant to the Agreement and Plan of Merger, dated as of January 2, 2019 ("
Merger Agreement
"), among the Company, Merger Sub
                  and Celgene. In addition, this Registration Statement registers 29,480,861 shares of Common Stock issuable to current employees of Celgene and future employees of the Company under the BMS Stock Plans (as defined below).  Pursuant to Rule
                  416(A), the number of shares and CVRs being registered shall be adjusted to include any additional shares and CVRs which may become issuable as a result of stock splits, stock dividends or similar transactions in accordance with the
                  anti-dilution provisions of the BMS Stock Plans and agreements evidencing outstanding awards thereunder.
(2)
Estimated solely for the purpose of computing the registration fee pursuant to Rule 457(h) and Rule 457(c) under the Securities Act of 1933 ("
Securities Act
"), as amended. The price per share of
                  Common Stock is based on the average of the high and low prices reported for a share of Common Stock on the New York Stock Exchange on November 20, 2019.
(3)
Estimated solely for the purpose of computing the registration fee pursuant to Rule 457(h) and Rule 457(c) under the Securities Act. The price per CVR is based on the average of the high and low prices reported for a CVR on the New
                  York Stock Exchange on November 21, 2019.
(4)
Determined in accordance with Section 6(b) of the Securities Act at a rate equal to $129.80 per $1,000,000 of the proposed maximum aggregate offering price.
EXPLANATORY NOTE
On November 20, 2019, upon the effectiveness of the Merger (the "
Effective Time
"), Celgene became a wholly-owned subsidiary of the Company. Pursuant to the Merger Agreement, at the
      Effective Time:
1.
Each Celgene In-the-Money Option (as defined herein) was assumed by the Company and converted into (i) an option (an "
Assumed In-the-Money Option
") to purchase, on the same terms and conditions
                  as applied to each such Celgene In-the-Money Option immediately prior to the Effective Time, shares of Common Stock, except that (A) the number of shares of Common Stock subject to such Assumed In-the-Money Option is equal to the product
                  of (x) the number of shares of Celgene common stock that were subject to such Celgene In-the-Money Option immediately prior to the Effective Time, multiplied by (y) the Equity Award Exchange Ratio (as defined herein) (rounded down to the
                  nearest whole number), and (B) the per-share exercise price is equal to the quotient of (x) the exercise price per share of Celgene common stock at which such Celgene In-the-Money Option was exercisable, divided by (y) the Equity Award
                  Exchange Ratio (rounded up to the nearest whole cent), and (ii) the right to receive (A) if such Celgene In-the-Money Option was vested prior to the Effective Time, one CVR for each share of Celgene common stock underlying such Celgene
                  In-the-Money Option immediately prior to the Effective Time or (B) if such Celgene In-the-Money Option was not vested immediately prior to the Effective Time, immediately upon, and subject to, the vesting of the Assumed In-the Money
                  Option, the Unvested Equity Award CVR Consideration (as defined herein). Each Assumed In-the-Money Option will continue to have the same terms and conditions as applied to the corresponding Celgene In-the-Money Option immediately prior to
                  the Effective Time.
2.
Each Celgene Out-of-the-Money Option
(as defined herein)
was assumed by the Company and converted into an option (an "
Assumed Out-of-the-Money Stock Option
") to purchase, on the same terms and conditions as applied to each such Celgene Out-of-the-Money Option immediately prior to the
                    Effective Time, shares of Common Stock, except that the number of shares of Common Stock subject to such Assumed Out-of-the-Money Stock Option is equal to the product of (i) the number of shares of Celgene common stock that were subject
                    to such Celgene Out-of-the-Money Option immediately prior to the Effective Time, multiplied by (ii) the Out-of-the-Money Option Exchange Ratio (as defined herein) (rounded down to the nearest whole number), and the per-share exercise
                    price is equal the quotient of (A) the exercise price per share of Celgene common stock at which such Celgene Out-of-the-Money Option was exercisable, divided by (B) the Out-of-the-Money Option Exchange Ratio (rounded up to the nearest
                    whole cent). Each Assumed Out-of-the-Money Stock Option will continue to have the same terms and conditions as applied to the corresponding Celgene Out-of-the-Money Option immediately prior to the Effective Time.
3.
Each restricted stock unit award with respect to shares of Celgene common stock outstanding under any Celgene Stock Plan (as defined herein) that vests solely based on the passage of time ("
Celgene RSU Award
") was assumed by the Company and converted into (i) a restricted unit award (an "
Assumed

                    Restricted Unit Award
") that settles in a number of shares of Common Stock equal to (A) the number of shares of Celgene common stock underlying the Celgene RSU Award immediately prior to the
                    Effective Time, multiplied by (B) the Equity Award Exchange Ratio (rounded up to the nearest whole number of shares) and (ii) the right to receive, subject to the vesting of the Assumed Restricted Unit Award, the Unvested Equity Award
                    CVR Consideration. Each Assumed Restricted Unit Award will continue to have the same terms and conditions as applied to the corresponding Celgene RSU Award immediately prior to the Effective Time.
4.
Each restricted stock unit award with respect to shares of Celgene common stock outstanding under any Celgene Stock Plan that vests based on the achievement of performance goals ("
Celgene PSU Award
") was assumed by the Company and converted into (i) a restricted stock unit award (an "
Assumed Performance Unit Award
") that settles in a number of shares of Common Stock equal to the product of (A) the number of shares of Celgene common stock underlying the Celgene PSU Award
                    immediately prior to the Effective Time (determined by deeming the applicable performance goals to be achieved at the greater of the target level and the actual level of achievement through the end of the calendar quarter immediately
                    preceding the Effective Time) multiplied by (B) the Equity Award Exchange Ratio (rounded up to the nearest whole number of shares), and (ii) the right to receive, subject to the vesting of the Assumed Performance Unit Award, the
                    Unvested Equity Award CVR Consideration. Each Assumed Performance Unit Award will continue to have the same terms and conditions as applied to the corresponding Celgene PSU Award (other than performance-based vesting conditions)
                    immediately prior to the Effective Time.
2
5.
Each restricted stock award with respect to shares of Celgene common stock outstanding under any Celgene Stock Plan that vests based on the passage of time and/or the achievement of performance goals ("
Celgene RSA
") was assumed by the Company and converted into (i) a restricted stock award (an "
Assumed

                    Restricted Stock Award
") that settles in a number of shares of Common Stock equal to (A) the number of shares of Celgene common stock underlying the Celgene RSA immediately prior to the Effective
                    Time multiplied by (B) the Equity Award Exchange Ratio (rounded up to the nearest whole number of shares), and (ii) the right to receive, subject to the vesting of the Assumed Restricted Stock Award, the Unvested Equity Award CVR
                    Consideration. Each Assumed Restricted Stock Award will continue to have the same terms and conditions as applied to the corresponding Celgene RSA.
For purposes of this Registration Statement:
"
BMS Stock Plans
" means the Bristol-Myers Squibb Company 2017 Stock Incentive Plan (F/K/A Celgene Corporation 2017 Stock Incentive Plan) and the Bristol-Myers
      Squibb Company 2014 Equity Incentive Plan (F/K/A Celgene Corporation 2014 Equity Incentive Plan), each of which was formerly a Celgene equity incentive plan and was assumed by the Company in connection with the Merger.
"
Celgene In-the-Money Option
" means a compensatory option to purchase shares of Celgene common stock under any Celgene Stock Plan for which the per share
      exercise price as of immediately prior to the Effective Time is less than the Celgene Stock Price.
"
Celgene Stock Plans
" means the Celgene Corporation 2017 Stock Incentive Plan and the Celgene Corporation 2014 Equity Incentive Plan. In connection with the
      Merger, the Celgene Corporation 2017 Stock Incentive Plan was assumed, amended and renamed by the Company as the Bristol-Myers Squibb Company 2017 Stock Incentive Plan. The Celgene Corporation 2014 Equity Incentive Plan was assumed, amended and
      renamed by the Company as the Bristol-Myers Squibb Company 2014 Equity Incentive Plan.
"
Celgene Stock Price
" means $109.4009.
"
Celgene Out-of-the-Money Option
" means a compensatory option to purchase shares of Celgene common stock under any Celgene Stock Plan for which per share
      exercise price as of immediately prior to the Effective Time equals or exceeds the Celgene Stock Price.
"
CVR Agreement
" means the Contingent Value Rights Agreement, dated November 20, 2019 among the Company and Equiniti Trust Company, as trustee, in favor of each
      person who from time to time holds one or more CVRs.
"
Equity Award Exchange Ratio
" means 1.86.
"
Out-of-the-Money Option Exchange Ratio
" means 1.87.
"
Unvested Equity Award CVR Consideration
" means, if the vesting date of the unvested Celgene In-the-Money Option, the Celgene RSU Award, the Celgene PSU Award or
      the Celgene RSA, as applicable, occurs (i) prior to the milestone payment record date and the termination date under the CVR Agreement, one CVR in respect of each share of Celgene common stock underlying such Celgene In-the-Money Option, Celgene RSU
      Award, Celgene PSU Award, or Celgene RSA, as applicable, immediately prior to the Effective Time, (ii) on or after the milestone payment record date under the CVR Agreement, a cash payment equal to the milestone payment under the CVR Agreement in
      respect of each share of Celgene common stock underlying such In-the-Money Option, Celgene RSU Award, Celgene PSU Award or Celgene RSA, as applicable, immediately prior to the Effective Time, or (iii) on or after the termination date under the CVR
      Agreement and the CVR milestone under the CVR Agreement was not achieved prior to such termination date, no additional consideration.
3
PART I
The information required by Item 1 and Item 2 of Part I of Form S-8 is omitted from this filing in accordance with Rule 428 under the Securities Act and the introductory note to Part I of Form S-8.
      The documents containing the information specified in Part I will be delivered to the participants in the plan covered by this Registration Statement as required by Rule 428(b)(1).
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.
Incorporation of Documents by Reference
The following documents filed with the Securities and Exchange Commission (the "
Commission
") by Company pursuant to the Securities Act and the Securities
      Exchange Act of 1934, as amended (the "
1934 Act
") are incorporated herein by reference:
(a) The Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018
(filed
      with the Commission on February 25, 2019).
(b) The information specifically incorporated by reference into the Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018
from the Company's definitive proxy statement on Schedule 14A (filed with the Commission on
April 30, 2019
).
(c) The Company's Quarterly Reports on Form 10-Q for the quarter ended
March 31, 2019
(filed with
      the Commission on April 25, 2019), for the quarter ended
June 30, 2019
(filed with the Commission on July 25, 2019) and for the quarter ended
September 30, 2019
(filed with the Commission on October 31, 2019).
(d) The Company's Current Reports on Form 8-K filed with the Commission on
January 3, 2019
,
January 4, 2019
,
January 22, 2019
,
January 30, 2019
,
March 8, 2019
,
March 8, 2019
,
March 26, 2019
,
April 4, 2019
,
April 12, 2019
,
April 17, 2019
,
May 1, 2019
,
May 1, 2019
,
May 2, 2019
,
May 8, 2019
,
May 16, 2019
,
May 24, 2019
,
May 30, 2019
,
June 5, 2019
,
June 24, 2019
,
June 28, 2019
,
July 1, 2019
,
August 26, 2019
,
September 12, 2019
,
September 23, 2019
,
October 8, 2019
,
October 18, 2019
,
October 30, 2019
,
November 1, 2019
,
November 5, 2019
,
November 7, 2019
,
November 12, 2019
,
November 15, 2019
,
November 15, 2019
,
November 20, 2019
and
November 22, 2019
.
(e) The description of the Company's capital stock and the CVRs, which is contained in the Company's Registration Statement on
Form S-4
(No. 333-229464) (filed with the Commission on February 1, 2019), including any amendments or supplements thereto.
(f) All future reports filed pursuant to Section 13(a) and 15(d) of the 1934 Act by the Company since the end of the fiscal year covered by the annual report referred to in (a) above; provided,
      however, that the foregoing shall not include the incorporation by reference of any information furnished pursuant to Items 2.02, 7.01 or 9.01 of Form 8-K.
In addition, all documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this
      Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in the Registration Statement and to be a part hereof from the
      date of the filing of such documents (other than current reports furnished under Items 2.02, 7.01 or 9.01 of Form 8-K). Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified
      or superseded for purposes of this Registration Statement to the extent that a statement contained herein (or in any other subsequently filed document which also is incorporated or deemed to be incorporated by reference herein) modifies or supersedes
      such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
4
Item 4.
Description of Securities.
Not applicable.
Item 5.
Interests of Named Experts and Counsel.
None.
Item 6.
Indemnification of Directors and Officers.
Section 145 of the Delaware General Corporation Law (the "DGCL") provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses
      (including attorneys' fees), judgments, fines and amounts paid in settlement in connection with specified actions, suits or proceedings, whether civil, criminal, administrative or investigative (other than an action by or in the right of the
      corporation—a "derivative action"), if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal actions or proceedings, had no reasonable
      cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses (including attorneys' fees) actually and reasonably incurred in connection with the
      defense or settlement of such action, and the DGCL requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. The DGCL provides that it is not exclusive of other
      indemnification that may be granted by a corporation's by-laws, disinterested director vote, stockholder vote, agreement or otherwise.
Under the terms of our Bylaws and subject to the applicable provisions of Delaware law, we have agreed to indemnify each of our directors and officers and, subject to the discretion of the board of
      directors, any other person, against expenses incurred or paid in connection with any claim made against such director or officer or any actual or threatened action, suit or proceeding in which such director or officer may be involved by reason of
      being or having been a director or officer of us, or of serving or having served at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action taken
      or not taken by such director or officer in such capacity, and against the amount or amounts paid by such director or officer in settlement of any such claim, action, suit or proceeding or any judgment or order entered therein.
Section 102(b)(7) of the DGCL permits a provision in the certificate of incorporation of each corporation organized thereunder, such as the Company, eliminating or limiting, with certain exceptions,
      the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. The Company's Amended and Restated Certificate of Incorporation eliminates the liability of directors
for monetary damages for breach of fiduciary duty
to the extent permitted by the DGCL.
The Company carries directors' and officers' liability insurance that covers certain liabilities and expenses of its directors and officers.
Item 7.
Exemption from Registration Claimed.
Not applicable.
5
Item 8.
Exhibits.
Exhibit
Number
4.1
Amended and Restated Certificate of Incorporation of Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit 3a to Bristol Myers-Squibb Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30,
              2005).
4.1A
Certificate of Correction to the Amended and Restated Certificate of Incorporation, effective as of December 24, 2009 (incorporated herein by reference to Exhibit 3b to Bristol Myers-Squibb Company's Annual Report on Form 10-K for the
              fiscal year ended December 31, 2010).
4.1B
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective as of May 7, 2010 (incorporated herein by reference to Exhibit 3a to Bristol Myers-Squibb Company's Current Report on Form 8-K filed on May 10,
              2010).
4.1C
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective as of May 7, 2010 (incorporated herein by reference to Exhibit 3b to Bristol Myers-Squibb Company's Current Report on Form 8-K filed on May 10,
              2010).
4.2
Bylaws of Bristol-Myers Squibb Company, as amended as of November 2, 2016 (incorporated herein by reference to Exhibit 3.1 to Bristol Myers-Squibb Company's Current Report on Form 8-K filed on November 4, 2016).
4.3
Contingent Value Rights Agreement, between Bristol Myers Squibb Company and Equiniti Trust Company, dated November 20, 2019 (incorporated by reference to Exhibit 4.1 to Bristol Myers-Squibb Company's Form 8-K dated November 20, 2019 and
              filed on November 20, 2019).
5.1*
Opinion of Kirkland & Ellis LLP.
23.1*
Consent of Deloitte & Touche LLP Independent Registered Public Accounting Firm of Bristol-Myers Squibb Company.
23.2*
Consent of KPMG LLP, independent registered public accounting firm of Celgene Corporation.
23.3*
Consent of Kirkland & Ellis LLP (included in Exhibit 5.1).
24.1
Powers of Attorney (included in the signature pages hereof).
99.1*
Bristol-Myers Squibb Company 2017 Stock Incentive Plan (F/K/A Celgene Corporation 2017 Stock Incentive Plan).
99.2 *
Bristol-Myers Squibb Company 2014 Equity Incentive Plan (F/K/A Celgene Corporation 2014 Equity Incentive Plan).
*
Filed herewith
Item 9.
Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement;
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which,
      individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
      securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (§
      230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration
      statement;
(iii) To include any material information with respect to the plans of distribution not previously disclosed in this registration statement or any material change to such
      information in this registration statement;
provided
,
however
, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included
      in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are
      incorporated by reference in this registration statement.
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
      relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
6
(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant's annual report pursuant to Section
      13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the
      registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant, pursuant to the foregoing
      provisions or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
      that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or
      proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a
      court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
7
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8
      and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on the 25th day of November, 2019.
BRISTOL-MYERS SQUIBB COMPANY
By:
/s/
Sandra Leung
Sandra Leung
Executive Vice President and General Counsel
8
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints Sandra Leung and Katherine R. Kelly as his or her true and lawful attorneys-in-fact and agents, with full power
        of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign the name of each of the undersigned in his or her capacity to any and all amendments (including any post-effective
        amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto such said attorney-in-fact and agent full power and
        authority to do and perform each and every act and thing necessary or advisable to be done, as fully to all intents and purposes as the undersigned might or could do in person, and each of the undersigned hereby ratifies and confirms that the said
        attorney-in-fact or agent shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Giovanni Caforio
Chief Executive Officer and Director
(Principal Executive Officer)
November 25, 2019
Giovanni Caforio, M.D.
/s/ David V. Elkins
Chief Financial Officer
(Principal Financial Officer)
November 25, 2019
David V. Elkins
/s/ Karen M. Santiago
Senior Vice President and Corporate Controller
(Principal Accounting Officer)
November 25, 2019
Karen M. Santiago
/s/ Vicki L. Sato
Lead Independent Director
November 25, 2019
Vicki L. Sato, Ph.D.
/s/ Peter J. Arduini
Director
November 25, 2019
Peter J. Arduini
/s/ Robert Bertolini
Director
November 25, 2019
Robert Bertolini
/s/ Matthew W. Emmens
Director
November 25, 2019
Matthew W. Emmens
/s/ Michael Grobstein
Director
November 25, 2019
Michael Grobstein
9
/s/ Alan J. Lacy
Director
November 25, 2019
Alan J. Lacy
/s/ Dinesh C. Paliwal
Director
November 25, 2019
Dinesh C. Paliwal
/s/ Theodore R. Samuels
Director
November 25, 2019
Theodore R. Samuels
/s/ Gerald L. Storch
Director
November 25, 2019
Gerald L. Storch
/s/ Karen H. Vousden
Director
November 25, 2019
Karen H. Vousden, Ph.D.
10
EXHIBIT INDEX
4.1
Amended and Restated Certificate of Incorporation of Bristol-Myers Squibb Company (incorporated herein by reference to Exhibit 3a to Bristol Myers-Squibb Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30,
              2005).
4.1A
Certificate of Correction to the Amended and Restated Certificate of Incorporation, effective as of December 24, 2009 (incorporated herein by reference to Exhibit 3b to Bristol Myers-Squibb Company's Annual Report on Form 10-K for the
              fiscal year ended December 31, 2010).
4.1B
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective as of May 7, 2010 (incorporated herein by reference to Exhibit 3a to Bristol Myers-Squibb Company's Current Report on Form 8-K filed on May 10,
              2010).
4.1C
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective as of May 7, 2010 (incorporated herein by reference to Exhibit 3b to Bristol Myers-Squibb Company's Current Report on Form 8-K filed on May 10,
              2010).
4.2
Bylaws of Bristol-Myers Squibb Company, as amended as of November 2, 2016 (incorporated herein by reference to Exhibit 3.1 to Bristol Myers-Squibb Company's Current Report on Form 8-K filed on November 4, 2016).
4.3
Contingent Value Rights Agreement, between Bristol Myers Squibb Company and Equiniti Trust Company, dated November 20, 2019 (incorporated by reference to Exhibit 4.1 to Bristol Myers-Squibb Company's Form 8-K dated November 20, 2019 and
              filed on November 20, 2019).
5.1*
Opinion of Kirkland & Ellis LLP.
23.1*
Consent of Deloitte & Touche LLP Independent Registered Public Accounting Firm of Bristol-Myers Squibb Company.
23.2*
Consent of KPMG LLP, independent registered public accounting firm of Celgene Corporation.
23.3*
Consent of Kirkland & Ellis LLP (included in Exhibit 5.1).
24.1
Powers of Attorney (included in the signature pages hereof).
99.1*
Bristol-Myers Squibb Company 2017 Stock Incentive Plan (F/K/A Celgene Corporation 2017 Stock Incentive Plan).
99.2*
Bristol-Myers Squibb Company 2014 Equity Incentive Plan (F/K/A Celgene Corporation 2014 Equity Incentive).  Plan).
*Filed herewith
11